NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE
Delisted
NBSE was delisted on the 10th of May, 2024.
45 hedge funds and large institutions have $23.3M invested in NeuBase Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
26% less capital invested
Capital invested by funds: $31.6M → $23.3M (-$8.32M)
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
Holders
45
Holding in Top 10
1
Calls
$56K
Puts
$15K
Top Buyers
| 1 | +$329K | |
| 2 | +$174K | |
| 3 | +$111K | |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$84.1K |
| 5 |
D.E. Shaw & Co
New York
|
+$70K |
Top Sellers
| 1 | -$574K | |
| 2 | -$83K | |
| 3 | -$56K | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$28.2K |
| 5 |
Two Sigma Advisers
New York
|
-$27.9K |